Pharming Group has nominated Fabrice Chouraqui as the successor to CEO Sijmen de Vries. His appointment will be subject to approval at an Extraordinary General Meeting of Shareholders (EGM).
Upon his appointment, Chouraqui will join the Board of Directors, while De Vries will step down as CEO. To ensure a smooth transition, De Vries will remain as a strategic advisor until December 31, 2025.
Richard Peters, Chairman of the Board of Directors, highlighted the expertise Chouraqui brings to Pharming:
“Fabrice is a highly experienced leader in the international pharmaceutical and biotechnology sectors. He brings extensive global expertise across the entire biopharmaceutical value chain, which will support Pharming in its next phase of growth.”
Chouraqui has held senior leadership roles at Novartis and Bristol-Myers Squibb, bringing a wealth of industry knowledge to Pharming.
With this appointment, Pharming reinforces its commitment to continuity and international expansion in the biotech sector.
On Tuesday 16 December, Leiden University Medical Center welcomed His Majesty King Willem-Alexander and Minister Jan Anthonie Bruijn of the Ministry of Health, Welfare and Sport...
Vanmiddag nam minister Jan Anthonie Bruijn van het ministerie van Volksgezondheid, Welzijn en Sport in Leiden, bij het LUMC, het rapport ‘Nederland in de voorhoede: rode biotech...
Two Zuid-Holland startups are bringing breakthrough technology into clinical practice. Axite from Leiden and Hologenomix from Delft each receive a €350,000 investment from the...